Search Results
372 results
Your search is now limited to «Bristol-Myers Squibb» expert search.
Drug & Device Law 01/22/2019 05:00
In BMS, the Supreme Court held that California’s courts could not exercise specific personal jurisdiction over an out-of-state defendant unless there is “an affiliation between the forum and the underlying controversy, principally, [an] activity or ...
More from Drug & Device Law:
Zacks.com 01/21/2019 07:50
Bristol-Myers’ shares have decreased 8.9% in the past six months, against the industry’s growth of 7.1.
More from Zacks.com:
Korean Biomedical Review 01/21/2019 04:04
Bristol-Myers Squibb (BMS) and Ono Pharma Korea have received an additional indication for using a combination treatment of Opdivo and Yervoy a first-line therapy in treating renal cell carcinoma (RCC), in Europe.
More from Korean Biomedical Review:
MedCity News 01/18/2019 14:12
Bristol-Myers Squibb agreed to acquire Celgene for $74 billion earlier this month.
More from MedCity News:
ENDPOINTS 01/18/2019 07:15
Celgene bets $80M on immunometabolism in first partnership deal since Bristol-Myers announced $74B buyout – Endpoints News.
More from ENDPOINTS:
Motley Fool 01/17/2019 10:00
What happened Biopharma heavyweight Bristol-Myers Squibb (NYSE:BMY) saw its shares sink by a staggering 15.2% in 2018, according to data from S&P Global Market Intelligence.
More from Motley Fool:
pharmaphorum 01/16/2019 04:19
Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal cell carcinoma (RCC), the most ...
More from pharmaphorum:
Seeking Alpha 01/15/2019 14:45
With management pledging to deleverage quickly, and Bristol likely to maintain an "A" credit rating equivalent courtesy of $11 billion in retained FCF, thanks to a 26% payout ratio, dividend investors can definitely consider Bristol a "sleep well at night" or SWAN stock.
More from Seeking Alpha:
FiercePharmaMarketing 01/15/2019 10:55
Exelixis enters crowded liver cancer field with Cabometyx, taking on Bayer, BMS and Merck.
More from FiercePharmaMarketing:
FiercePharmaManufacturing 01/15/2019 09:58
RELATED: Bristol-Myers scores first big deal of 2019 with $74B buyout of oncology bigwig Celgene BMS and Celgene are unfazed by the criticism.
More from FiercePharmaManufacturing:
PharmaBiz.com 01/15/2019 07:37
Bristol-Myers receives European approval for Opdivo plus low dose Yervoy to treat patients with intermediate- and advanced RCC.
More from PharmaBiz.com:
Healio News 01/10/2019 10:43
Bristol-Myers Squibb to acquire Celgene in $74 billion deal Bristol-Myers Squibb has agreed to acquire Celgene in one of the largest mergers in the pharmaceutical industry’s history.
More from Healio News:
GeekWire 01/10/2019 09:00
The combined portfolio of Bristol-Myers Squibb and Celgene includes nine drugs, each with over $1 billion in annual sales – including the cancer drug Opdivo, a ‘checkpoint inhibitor’ from Bristol-Myers Squibb, designed to boost the immune response against cancer cells ...
More from GeekWire:
Business Insider 01/09/2019 13:04
Often looked at as a potential takeover target, it's possible BMS could get acquired itself, particularly from companies looking to beef up their presence in cancer immunotherapy.
More from Business Insider:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications